聚焦资本市场创新"赛道" 编者按 在资本市场中，行业板块的动态一直是投资者关注的焦点。近期，创新药、CPO概念（算力）与半导体、人工智能等板块热度居高不下，创新"赛道"备受 市场关注。创新药关乎人类健康与医疗进步，在政策扶持、技术突破下蓬勃发展，具备全球竞争力的企业将通过差异化创新和国际化布局打开成长天花 板；受益于全球AI算力需求爆发及技术迭代加速，CPO概念板块下半年将维持高景气度；人工智能行业进入快速发展期，技术的深度应用推动相关企业商 业化发展，盈利整体增加。本期《资本市场》聚焦创新行业，以期为市场提供有价值的参考。 | 数读市场 | | --- | | 8月1日,A股震荡走低,英伟达产业链调整,创新药、 | | 中药题材继续强势,AI硬件、应用概念股此消彼长。截 | | 至收盘,上证指数报3559.95点,深证成指报10991.32 | | 点。 | | 7月28日至8月1日,A股市场整体呈现回调态势,多数宽 | | 基指数下跌。Wind百大概念指数上涨比例43%。在板块 | | 方面,仅19%板块获得正收益,医药生物、通信、传媒 | | 相对表现良好,分别上涨2.95%、2.54%、1.13%。 ...

中银国际发表研究报告指，药明康德(02359.HK)上半年业绩表现强劲，收入及净利润增长稳健，利润率 扩张，TIDES业务表现突出，同时化学业务韧性增长，有助抵销临床CRO及测试业务的疲软。管理层上 调2025年收入指引至介乎425亿至435亿元人民币，即持续经营业务料增长13%至17%，资本开支维持70 亿至80亿元人民币不变。中银国际将药明康德今明两年盈利预测上调15%及22%，目标价从81港元升至 122港元，维持"买入"评级。 中银国际维持药明康德"买入"评级 目标价升至122港元 ...

Group 1 - The stock prices of several biotech companies have experienced declines, with 康方生物 (09926.HK) down 5.37%, 泰格医药 (03347.HK) down 3.34%, 药明康德 (02359.HK) down 3.15%, and 君实生物 (01877.HK) down 2.64% [1]

港股医药股震荡走低，华润医疗跌超13%，石药集团、复星医药、微创医疗、药明康德、药明生物等跟 跌。 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug licensing collaborations [1]. Core Insights - The pharmaceutical and biotechnology sector experienced a weekly increase of 2.08%, outperforming the Wind All A index (-1.09%) and the CSI 300 index (-1.75%) during the week of July 28 to August 1 [2][7]. - Significant collaborations in innovative drug licensing were highlighted, including a $500 million upfront payment from Hengrui Medicine to GlaxoSmithKline for the licensing of HRS-9821 and 11 other projects [2][12]. - The report notes a shift in the focus of innovative drug assets from oncology to a broader range of therapeutic areas, including respiratory, metabolic, and immune diseases, indicating an increase in global competitiveness of domestic innovative drugs [2][12]. Weekly Market Review - The chemical preparations sector led the gains with a 5.48% increase, followed by other biological products (5.36%) and medical research outsourcing (4.07%). In contrast, medical devices (-1.43%), blood products (-0.7%), and hospitals (-0.69%) saw declines [2][10]. - Notable individual stock performances included Nanjing New Drug Co. (78%), Lide Man (46.4%), and Chenxin Pharmaceutical (40.9%) as top gainers, while *ST Suwu (-15.1%), Sanofi Biologics (-10.1%), and Botao Biologics (-9.5%) were the biggest losers [2][11]. Industry News and Key Company Announcements - The report mentions that Anhui Province has initiated the collection of information on biosimilar drugs, with plans to start centralized procurement for monoclonal antibodies in early 2025 [2]. - Key events included the announcement of a strategic investment by GSK in Hengrui Medicine, and a licensing agreement between CSPC and Madrigal for the oral GLP-1 receptor agonist SYH2086, which could yield up to $20.75 billion in potential revenue [2][12][13]. - The report also highlights the approval of various drugs and clinical trials, including the positive preliminary data for IMM2510 in treating non-small cell lung cancer [12][13][14].

Group 1 - A total of 2,090 stocks received net financing purchases this week, with 1,103 stocks having net purchases exceeding 10 million yuan [1] - 118 stocks had net purchases exceeding 100 million yuan, and 5 stocks had net purchases exceeding 1 billion yuan [1] - New Yisheng topped the list with a net purchase amount of 1.6 billion yuan, followed by Ningde Times, WuXi AppTec, and Kweichow Moutai with net purchases of 1.351 billion yuan, 1.123 billion yuan, and 1.067 billion yuan respectively [1] Group 2 - CITIC Securities, Dongshan Precision, and Muyuan Foods experienced the highest net sell-offs, with amounts of 1.18 billion yuan, 714 million yuan, and 344 million yuan respectively [1]

Market Overview - During the trading days from July 28 to August 1, all three major A-share indices experienced a pullback, with the Shanghai Composite Index down by 0.94%, the Shenzhen Component Index down by 1.58%, and the ChiNext Index down by 0.74% [1] - The Shanghai Composite Index closed at 3560 points with a trading volume of 684.6 billion yuan on Friday [3] Sector Performance - The pharmaceutical sector showed strong performance this week, with several stocks in the AI application, electronics, photovoltaic, and solid-state battery sectors also being active [1] - A total of 20 stocks saw a price increase of over 30%, with Nanjing New Pharmaceutical leading with a cumulative increase of 78.01% [4] Notable Stocks - Nanjing New Pharmaceutical's significant rise is attributed to its announcement regarding the potential acquisition of domestic pharmaceutical technology assets, although the deal is still in the planning stage and carries uncertainty [4] - Other notable gainers include Dongxin Co. (53.68%), Southern Road Machinery (53.38%), and Siquan New Materials (50.75%) [5] Trading Activity - A total of 71 stocks had a turnover rate exceeding 100%, with Beifang Changlong leading at 257.92% [6] - The sectors with high turnover rates included electronics, machinery equipment, and pharmaceuticals [6] Fund Flow - The banking and transportation sectors were favored by institutional investors, receiving net inflows of 2.224 billion yuan and 990 million yuan, respectively [8] - Conversely, sectors such as computers, non-ferrous metals, and electronics faced significant net sell-offs, each exceeding 10 billion yuan [8] Institutional Research - DeFu Technology attracted the most attention from institutions, with 238 firms participating in its research [14] - The focus of institutional research remains on sectors like electronic components, photovoltaic equipment, and industrial machinery [14] Financing Activity - New Yisheng topped the list for financing net purchases, amounting to 1.6 billion yuan, followed by Ningde Times and WuXi AppTec with 1.351 billion yuan and 1.123 billion yuan, respectively [12]

Group 1 - A total of 2090 stocks received net financing purchases this week, with 1103 stocks having net purchases exceeding 10 million yuan, 118 stocks exceeding 100 million yuan, and 5 stocks exceeding 1 billion yuan [1] - New Yisheng topped the list with a net purchase amount of 1.6 billion yuan, followed by Ningde Times, WuXi AppTec, and Kweichow Moutai with net purchases of 1.351 billion yuan, 1.123 billion yuan, and 1.067 billion yuan respectively [1] - CITIC Securities, Dongshan Precision, and Muyuan Foods experienced the highest net sell-offs, with amounts of 1.18 billion yuan, 714 million yuan, and 344 million yuan respectively [1]

截至2025年8月1日收盘，药明康德（603259）报收于93.0元，较上周的88.88元上涨4.64%。本周，药明 康德7月30日盘中最高价报102.49元，股价触及近一年最高点。7月28日盘中最低价报88.81元。药明康德 当前最新总市值2671.16亿元，在医疗服务板块市值排名1/50，在两市A股市值排名40/5149。 本周关注点 交易信息汇总 7月30日药明康德现790.8万元大宗交易。 股本股东变化 业绩披露要点 药明康德2025年中报显示，公司主营收入207.99亿元，同比上升20.64%；归母净利润85.61亿元，同比 上升101.92%；扣非净利润55.82亿元，同比上升26.47%；其中2025年第二季度，公司单季度主营收入 111.45亿元，同比上升20.37%；单季度归母净利润48.89亿元，同比上升112.78%；单季度扣非净利润 32.53亿元，同比上升36.7%；负债率27.93%，投资收益36.69亿元，财务费用2.06亿元，毛利率44.45%。 公司公告汇总 交易信息汇总：7月30日药明康德大宗交易成交790.8万元。 股本股东变化：截至2025年6月30日，药明康德股东户数 ...

8月1日，沪深两融数据显示，药明康德获融资买入额8.53亿元，居两市第3位，当日融资偿还额9.27亿 元，净卖出7402.64万元。 最近三个交易日，30日-1日，药明康德分别获融资买入13.10亿元、11.03亿元、8.53亿元。 融券方面，当日融券卖出0.63万股，净买入4.40万股。 ...